Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects

Healthy Clinical Trial

Official title:

A Trial to Investigate Pharmacokinetics, Safety and Tolerability of Insulin Degludec/Liraglutide (A3) Compared With Insulin Degludec and Liraglutide in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01319240
• Other study ID #: NN9068-3871
• Secondary ID: 2010-021190-36U1
• Status: Completed
• Phase: Phase 1
• First received: March 18, 2011
• Last updated: October 1, 2015
• Start date: March 2011
• Est. completion date: May 2011

Study information

• Verified date: October 2015
• Source: Novo Nordisk A/S
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

This trial is conducted in Europe. The aim of this trial is to compare the bioavailability of insulin degludec and liraglutide, when administered either combined or as separate administrations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: May 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)

• Body Mass Index (BMI) between 20.0 and 27.0 kg/m^2 (both inclusive)

• Body weight between 75 kg and 90 kg (both inclusive)

• Fasting plasma glucose below 6.1 mmol/L (110 mg/dL)

Exclusion Criteria:

• Known or suspected hypersensitivity to trial products or related products

• Previous participation in this trial. Participation is defined as randomised

• Previous participation in any other clinical trial involving other investigational products within the last 3 months before dosing in this trial

• Donation of any blood or plasma in the past month or in excess of 500 mL within the 3 month preceding screening (trial start) or surgery or trauma with more than 500 mL blood loss within the 3 month preceding screening

• History of or presence of cancer, or any clinically significant cardiovascular, respiratory,metabolic, renal, hepatic, gastrointestinal, endocrine, diabetes, haematological, dermatological,venereal, neurological, psychiatric diseases or other major disorders that might have impact on the trial, as judged by the Investigator (Trial Physician)

• Clinically significant abnormal haematology, biochemistry, lipids, urinalysis or coagulation screening tests, as judged by the Investigator (Trial Physician)

• Known hepatitis or known carrier of the hepatitis B surface antigen (HBsAg) or hepatitis C antibodies, or a positive result to the test for HIV (human immunodeficiency virus) antibodies and antigen

• Family or personal history of MEN2 (Multiple endocrine neoplasia syndrome type 2) or familial medullary thyroid carcinoma (FMTC)

• History of chronic pancreatitis or idiopathic acute pancreatitis

• Supine blood pressure at screening, after resting for 5 min, outside the range of 90-140 mmHg systolic or 50-90 mmHg diastolic (excluding white-coat hypertension; therefore, if a repeated measurement on a second screening visit shows values within the range, the subject can be included in the trial) or resting heart rate outside the range of 40-90 bpm

• Clinically significant abnormal ECG (Electrocardiogram) at screening (trial start)

• Significant history of alcoholism or drug/chemical abuse, or a positive result of the urine drug screen or alcohol breath test, or consuming more than 21 units of alcohol per week (one unit of alcohol equals about 250 mL of beer or lager, one glass of wine, or 20 mL spirits)

• Smoking more than 5 cigarettes, or the equivalent, per day and unable to refrain from smoking during the in-house periods

• Mental incapacity or language barriers which preclude adequate understanding or cooperation,unwillingness to participate in the trial or subjects that in the opinion of Investigator (trial physician) should not participate in the trial

• Use of any prescription or non-prescription medication, except for paracetamol, acetylsalicylic acid, and vitamins (but including mega-dose vitamin therapy, as judged by the Investigator (trial physician)) within 2 weeks before the trial

• Any condition that would interfere with trial participation or evaluation of results, as judged by the Investigator (trial physician)

• Subjects with a history of deep leg vein thrombosis or with frequent appearance of deep leg vein thrombosis in 1st degree relatives as judged by the Investigator (trial physician)

• Males who are sexually active and not surgically sterilised, who or whose partner are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)

• Baseline (screening) calcitonin level above or equal to 50 ng/L

• Suffer from a life threatening disease

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes
• Healthy

Intervention

Drug:
• insulin degludec
Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
• insulin degludec/liraglutide
Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
• liraglutide
Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The area under insulin degludec concentration-time curve		from 0-infinity hours after trial product administration	No
Primary	The area under liraglutide concentration-time curve		from 0-infinity hours after trial product administration	No
Secondary	The area under insulin degludec concentration-time curve		from 0-120 hours after trial product administration	No
Secondary	The area under liraglutide concentration-time curve		from 0-72 hours after trial product administration	No
Secondary	Maximum concentration of insulin degludec		from 0-120 hours after trial product administration	No
Secondary	Maximum concentration of liraglutide		from 0-72 hours after trial product administration	No
Secondary	Number of hypoglycaemic episodes		From day 0 to 7-14 days after 3rd trial product administration	No

External Links

•   Clinical Trials at Novo Nordisk